EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieKlinische Studie (Phase II)Klinische Studie (Phase III)Open Access · CC BY 4.0

Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT

Fiona Collinson iD, Kara-Louise Royle iD, Jayne Swain iD, Christy Ralph iD, Anthony Maraveyas iD, Tim Eisen iD, Paul Nathan iD, Robert Jones iD, David Meads iD, Tze Min Wah iD, Adam Martin iD, Janine Bestall iD und 20 weitere

Health Technology Assessment · 2024

DOI: 10.3310/jwtr4127 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Health Technology Assessment, 2024. Verfasst von Fiona Collinson und 31 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK. Hauptthemen laut MEDLINE: Kidney Neoplasms, Carcinoma, Renal Cell, Protein Kinase Inhibitors, Quality-Adjusted Life Years. Die Arbeit nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Technology Assessment programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is interest in using treatment breaks in oncology, to reduce toxicity without compromising efficacy. Trial design A Phase II/III multicentre, open-label, parallel-group, randomised controlled non-inferiority trial assessing treatment breaks in patients with renal cell carcinoma.

Methods

Participants Patients with locally advanced or metastatic renal cell carcinoma, starting tyrosine kinase inhibitor as first-line treatment at United Kingdom National Health Service hospitals.

Interventions

At trial entry, patients were randomised (1 : 1) to a drug-free interval strategy or a conventional continuation strategy. After 24 weeks of treatment with sunitinib/pazopanib, drug-free interval strategy patients took up a treatment break until disease progression with additional breaks dependent on disease response and patient choice. Conventional continuation strategy patients continued on treatment. Both trial strategies continued until treatment intolerance, disease progression on treatment, withdrawal or death.

Objective

To determine if a drug-free interval strategy is non-inferior to a conventional continuation strategy in terms of the co-primary outcomes of overall survival and quality-adjusted life-years. Co-primary outcomes For non-inferiority to be concluded, a margin of ≤ 7.5% in overall survival and ≤ 10% in quality-adjusted life-years was required in both intention-to-treat and per-protocol analyses. This equated to the 95% confidence interval of the estimates being above 0.812 and −0.156, respectively. Quality-adjusted life-years were calculated using the utility index of the EuroQol-5 Dimensions questionnaire.

Results

Nine hundred and twenty patients were randomised (461 conventional continuation strategy vs. 459 drug-free interval strategy) from 13 January 2012 to 12 September 2017. Trial treatment and follow-up stopped on 31 December 2020. Four hundred and eighty-eight (53.0%) patients [240 (52.1%) vs. 248 (54.0%)] continued on trial post week 24. The median treatment-break length was 87 days. Nine hundred and nineteen patients were included in the intention-to-treat analysis (461 vs. 458) and 871 patients in the per-protocol analysis (453 vs. 418). For overall survival, non-inferiority was concluded in the intention-to-treat analysis but not in the per-protocol analysis [hazard ratio (95% confidence interval) intention to treat 0.97 (0.83 to 1.12); per-protocol 0.94 (0.80 to 1.09) non-inferiority margin: 95% confidence interval ≥ 0.812, intention to treat: 0.83 > 0.812 non-inferior, per-protocol: 0.80 < 0.812 not non-inferior]. Therefore, a drug-free interval strategy was not concluded to be non-inferior to a conventional continuation strategy in terms of overall survival. For quality-adjusted life-years, non-inferiority was concluded in both the intention-to-treat and per-protocol analyses [marginal effect (95% confidence interval) intention to treat −0.05 (−0.15 to 0.05); per-protocol 0.04 (−0.14 to 0.21) non-inferiority margin: 95% confidence interval ≥ −0.156]. Therefore, a drug-free interval strategy was concluded to be non-inferior to a conventional continuation strategy in terms of quality-adjusted life-years.

Limitations

The main limitation of the study is the fewer than expected overall survival events, resulting in lower power for the non-inferiority comparison. Future work Future studies should investigate treatment breaks with more contemporary treatments for renal cell carcinoma.

Conclusions

Non-inferiority was shown for the quality-adjusted life-year end point but not for overall survival as pre-defined. Nevertheless, despite not meeting the primary end point of non-inferiority as per protocol, the study suggested that a treatment-break strategy may not meaningfully reduce life expectancy, does not reduce quality of life and has economic benefits. Although the treating clinicians’ perspectives were not formally collected, the fact that clinicians recruited a large number of patients over a long period suggests support for the study and provides clear evidence that a treatment-break strategy for patients with renal cell carcinoma receiving tyrosine kinase inhibitor therapy is feasible.

Trial registration

This trial is registered as ISRCTN06473203. Funding This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment Programme (NIHR award ref: 09/91/21) and is published in full in Health Technology Assessment ; Vol. 28, No. 45. See the NIHR Funding and Awards website for further award information.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney NeoplasmsCarcinoma, Renal CellProtein Kinase InhibitorsQuality-Adjusted Life YearsHumansMaleFemaleMiddle AgedAgedUnited KingdomWithholding TreatmentSunitinibTechnology Assessment, BiomedicalAdultAntineoplastic AgentsTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

CARCINOMA, RENAL CELLCLINICAL TRIALSCOST–BENEFIT ANALYSISDRUG ADMINISTRATION SCHEDULENON-INFERIORITY TRIALPAZOPANIBQUALITY-ADJUSTED LIFE-YEARSRANDOMISEDSUNITINIBSURVIVAL

Substanzen

Protein Kinase InhibitorsSunitinibAntineoplastic AgentsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Leeds Institute of Medical Research, St James's University Hospital, University of Leeds, Leeds, UK.
  • Academic Oncology, Faculty of Health Sciences, Hull York Medical School, Queens Centre Oncology and Haematology, Hull, UK.
  • Department of Oncology, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK.
  • Department of Oncology, Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, Hertfordshire, UK.
  • School of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK.

ORCID-Profile: Fiona Collinson, Kara-Louise Royle, Jayne Swain, Christy Ralph, Anthony Maraveyas, Tim Eisen, Paul Nathan, Robert Jones, David Meads, Tze Min Wah, Adam Martin, Janine Bestall, Christian Kelly-Morland, Christopher Linsley, Jamie Oughton, Kevin Chan, Elisavet Theodoulou, Gustavo Arias-Pinilla, Amy Kwan, Luis Daverede, Catherine Handforth, Sebastian Trainor, Abdulazeez Salawu, Christopher McCabe, Vicky Goh, David Buckley, Jenny Hewison, Walter Gregory, Peter Selby, Julia Brown, Janet Brown

Förderung

  • Health Technology Assessment programme

Zitieren

APA

Collinson, F., Royle, K. L., Swain, J., Ralph, C., Maraveyas, A., Eisen, T., Nathan, P., Jones, R., Meads, D., Min Wah, T., Martin, A., Bestall, J., Kelly-Morland, C., Linsley, C., Oughton, J., Chan, K., Theodoulou, E., Arias-Pinilla, G., Kwan, A., …, & all the STAR investigators (2024). Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT. Health Technology Assessment. https://doi.org/10.3310/jwtr4127

Vancouver

Collinson F, Royle KL, Swain J, Ralph C, Maraveyas A, Eisen T, et al. Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT. Health Technology Assessment. 2024. doi:10.3310/jwtr4127

BibTeX
@article{Collinson2024,
  author = {Collinson, Fiona and Royle, Kara-Louise and Swain, Jayne and Ralph, Christy and Maraveyas, Anthony and Eisen, Tim and Nathan, Paul and Jones, Robert and Meads, David and Min Wah, Tze and Martin, Adam and Bestall, Janine and Kelly-Morland, Christian and Linsley, Christopher and Oughton, Jamie and Chan, Kevin and Theodoulou, Elisavet and Arias-Pinilla, Gustavo and Kwan, Amy and Daverede, Luis and Handforth, Catherine and Trainor, Sebastian and Salawu, Abdulazeez and McCabe, Christopher and Goh, Vicky and Buckley, David and Hewison, Jenny and Gregory, Walter and Selby, Peter and Brown, Julia and Brown, Janet and all the STAR investigators, all the STAR investigators},
  title = {Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT},
  journal = {Health Technology Assessment},
  year = {2024},
  doi = {10.3310/jwtr4127}
}
Kostenlos starten →